AAO: Alimera highlights NEW DAY Study for sustained-release intravitreal implant

Video
Conference|AAO

Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.


Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
2 experts in this video
3 experts are featured in this series.
Related Content
An image of boxing gloves in a ring, hanging over an open flame. ©Image by Jennifer Toomey / MJH Life Sciences using AI

Up for debate: Clinicians take on hot topics at the Congress on Controversies in Ophthalmology

Hattie Hayes;Anat Loewenstein, MD;Baruch Kuppermann, MD, PhD
March 31st 2025
Article

This year, the COPHy meeting moves beyond retina, addressing uveitis, neuro-ophthalmology and glaucoma in Seville, Spain

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A blue eye with a large splash of blue liquid coming out of it. Vitreoretinal surgery ILM dye stain concept. Image credit: ©Sergey Nivens – stock.adobe.com

Internal limiting membrane staining dye ILM-Blue from DORC (Zeiss) receives NMPA approval in China

Hattie Hayes
March 27th 2025
Article

The approval makes ILM-Blue the first DORC posterior dye product available in China, according to a press release from Zeiss

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A person typing on a computer keyboard as icons representing documents and papers. Research paper publication concept image. Image credit: ©cherdchai – stock.adobe.com

Nanoscope Therapeutics publishes clinical results of MCO-010 findings for patients with retinitis pigmentosa

Martin David Harp
March 26th 2025
Article

The synthetic opsin was packaged into an optimised AAV2 gene therapy vector that targets human retinal bipolar cells.

The Moorfields Eye Hospital NHS Foundation Trust logo courtesy NHS Foundation Trust. Insitro logo courtesy Insitro. Lock and data point assets created with Canva.

Moorfields Eye Hospital INSIGHT research hub will collaborate with artificial intelligence development company Insitro

Hattie Hayes
March 24th 2025
Article

The partnership will use ocular imaging to build an AI foundation model and identify new genetic targets for degenerative diseases

© 2025 MJH Life Sciences

All rights reserved.